Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Cancer Biology, Genomics and Metabolomics
share announcement

Cancer Biology, Genomics and Metabolomics

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: closed (18 August 2023) | Viewed by 4705

Special Issue Editor

Dr. Spencer Rosario

E-Mail Website
Guest Editor
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Interests: metabolomics; transcriptomics; oncology; multi-omics integration; bioinformatics; immunoncology; immunometabolism

Special Issue Information

Dear Colleagues,

Nearly 100 years ago, Otto Warburg discovered and coined the “Warburg Effect”, a metabolic adaptation that increases biomass production and aids in the proliferation of tumor tissue. While our understanding of the metabolic alterations that underly cancer progression has remained relatively stagnant, in the past 20 years research aimed at understanding cellular energetics has exponentially increased. Much of this rise has been facilitated by the advancement of available research technologies, including improved bulk RNA sequencing, better mass spectrometers, and single-cell omics techniques. With this resurgence of research aimed at cancer metabolism, as well as the advancements in technology, this Special Issue will explore basic science, translational and clinical aspects of cancer biology, with a particular emphasis on ‘big data’-producing assays, and their implementation to better understand energy metabolism and metabolic reprogramming.

Dr. Spencer Rosario
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • metabolism
  • genomics
  • transcriptomics
  • energetics
  • metabolomics
  • bioinformatics

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

26 pages, 3722 KiB  
Article
Search for New Participants in the Pathogenesis of High-Grade Serous Ovarian Cancer with the Potential to Be Used as Diagnostic Molecules
by Angelika V. Timofeeva, Aleksandra V. Asaturova, Maya V. Sannikova, Grigory N. Khabas, Vitaliy V. Chagovets, Ivan S. Fedorov, Vladimir E. Frankevich and Gennady T. Sukhikh
Life 2022, 12(12), 2017; https://doi.org/10.3390/life12122017 - 03 Dec 2022
Cited by 3 | Viewed by 1508
Abstract
Recent studies have attempted to develop molecular signatures of epithelial ovarian cancer (EOC) based on the quantitation of protein-coding and non-coding RNAs to predict disease prognosis. Due to the heterogeneity of EOC, none of the developed prognostic signatures were directly applied in clinical [...] Read more.
Recent studies have attempted to develop molecular signatures of epithelial ovarian cancer (EOC) based on the quantitation of protein-coding and non-coding RNAs to predict disease prognosis. Due to the heterogeneity of EOC, none of the developed prognostic signatures were directly applied in clinical practice. Our work focuses on high-grade serous ovarian carcinoma (HGSOC) due to the highest mortality rate relative to other types of EOC. Using deep sequencing of small non-coding RNAs in combination with quantitative real-time PCR, we confirm the dualistic classification of epithelial ovarian cancers based on the miRNA signature of HGSOC (type 2), which differs from benign cystadenoma and borderline cystadenoma—precursors of low-grade serous ovarian carcinoma (type 1)—and identified two subtypes of HGSOC, which significantly differ in the level of expression of the progesterone receptor in the tumor tissue, the secretion of miR-16-5p, miR-17-5p, miR-93-5p, miR-20a-5p, the level of serum CA125, tumor size, surgical outcome (optimal or suboptimal cytoreduction), and response to chemotherapy. It was found that the combined determination of the level of miR-16-5p, miR-17-5p, miR-20a-5p, and miR-93-5p circulating in blood plasma of patients with primary HGSOC tumors makes it possible to predict optimal cytoreduction with 80.1% sensitivity and 70% specificity (p = 0.022, TPR = 0.8, FPR = 0.3), as well as complete response to adjuvant chemotherapy with 77.8% sensitivity and 90.9% specificity (p = 0.001, TPR = 0.78, FPR = 0.09). After the additional verification of the obtained data in a larger HGSOC patient cohort, the combined quantification of these four miRNAs is proposed to be used as a criterion for selecting patients either for primary cytoreduction or neoadjuvant chemotherapy followed by interval cytoreduction. Full article
(This article belongs to the Special Issue Cancer Biology, Genomics and Metabolomics)
►▼ Show Figures

Figure 1

Review

Jump to: Research

29 pages, 1539 KiB  
Review
Lithium: A Promising Anticancer Agent
by Edgar Yebrán Villegas-Vázquez, Laura Itzel Quintas-Granados, Hernán Cortés, Manuel González-Del Carmen, Gerardo Leyva-Gómez, Miguel Rodríguez-Morales, Lilia Patricia Bustamante-Montes, Daniela Silva-Adaya, Carlos Pérez-Plasencia, Nadia Jacobo-Herrera, Octavio Daniel Reyes-Hernández and Gabriela Figueroa-González
Life 2023, 13(2), 537; https://doi.org/10.3390/life13020537 - 15 Feb 2023
Cited by 8 | Viewed by 2900
Abstract
Lithium is a therapeutic cation used to treat bipolar disorders but also has some important features as an anti-cancer agent. In this review, we provide a general overview of lithium, from its transport into cells, to its innovative administration forms, and based on [...] Read more.
Lithium is a therapeutic cation used to treat bipolar disorders but also has some important features as an anti-cancer agent. In this review, we provide a general overview of lithium, from its transport into cells, to its innovative administration forms, and based on genomic, transcriptomic, and proteomic data. Lithium formulations such as lithium acetoacetate (LiAcAc), lithium chloride (LiCl), lithium citrate (Li3C6H5O7), and lithium carbonate (Li2CO3) induce apoptosis, autophagy, and inhibition of tumor growth and also participate in the regulation of tumor proliferation, tumor invasion, and metastasis and cell cycle arrest. Moreover, lithium is synergistic with standard cancer therapies, enhancing their anti-tumor effects. In addition, lithium has a neuroprotective role in cancer patients, by improving their quality of life. Interestingly, nano-sized lithium enhances its anti-tumor activities and protects vital organs from the damage caused by lipid peroxidation during tumor development. However, these potential therapeutic activities of lithium depend on various factors, such as the nature and aggressiveness of the tumor, the type of lithium salt, and its form of administration and dosage. Since lithium has been used to treat bipolar disorder, the current study provides an overview of its role in medicine and how this has changed. This review also highlights the importance of this repurposed drug, which appears to have therapeutic cancer potential, and underlines its molecular mechanisms. Full article
(This article belongs to the Special Issue Cancer Biology, Genomics and Metabolomics)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop